Won drug pricing lawsuit appeal, ordered to return 24.1 billion won
Seoul High Court ruled in favor of Korea United Pharm, dismissing all claims by National Health Insurance Service in drug pricing damages lawsuit appeal
Reversed first instance ruling that ordered payment of 24.1 billion won; plaintiff must return 24.1 billion won plus interest to the company
Amount represents 5.9% of equity (equity: 406.2 billion won as of end-2024)
Company to file corrective disclosure after receiving verdict; plans to respond through legal procedures including possible appeal to Supreme Court
KOSPI Filing Information
Filing: Judgment/Decision on Lawsuits, etc. (Claims of a Certain Amount or More)